Literature DB >> 2530358

Protein synthesis and degradation during regression of thyroxine-induced cardiac hypertrophy.

P S Coleman1, M S Parmacek, M Lesch, A M Samarel.   

Abstract

To characterize changes in rates of protein turnover during regression of thyroxine-induced left ventricular hypertrophy, New Zealand White rabbits received intravenous thyroxine (200 micrograms/kg/d) for 9 days. Thyroxine was withheld, and in vivo protein turnover was evaluated on the 10th, 15th and 20th days. Animals not receiving thyroxine served as controls. Heart rate, blood pressure, and rate-pressure product were measured to correlate changes in cardiac work with protein turnover rates during the development and regression of hypertrophy. Thyroxine administration produced left ventricular hypertrophy by increasing the rate of protein synthesis (from 37.9 +/- 8.9 to 64.1 +/- 15.3 mg/day; P less than 0.05) to a greater degree than protein degradation (from 29.8 +/- 8.9 to 48.2 +/- 15.3 mg/day for control and thyroxine-treated animals, respectively; P less than 0.05). Cessation of thyroxine administration resulted in an eventual return of left ventricular mass to that of normally growing control animals. The major observation noted during thyroxine withdrawal was a return of protein synthetic rates to normal. Absolute rates of protein degradation remained elevated, whereas fractional protein degradative rates (i.e. the fraction of total protein degraded per day) were unchanged by the administration and withdrawal of thyroxine. These results indicate that suppression of both physiological and hormone-induced growth following cessation of thyroxine resulted from a decrease in cardiac protein synthetic rates and an increased rate of flux through the protein degradative pathway(s), while fractional rates of protein degradation (and thus average protein half-life) remained unchanged. The development and regression of thyroxine-induced hypertrophy correlated with thyroxine-mediated alterations in cardiac work.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530358     DOI: 10.1016/0022-2828(89)90759-1

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

Review 1.  Thyroid hormone and blood pressure regulation.

Authors:  Sara Danzi; Irwin Klein
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

Review 2.  The ubiquitin-proteasome system and cardiovascular disease.

Authors:  Saul R Powell; Joerg Herrmann; Amir Lerman; Cam Patterson; Xuejun Wang
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 3.  Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.

Authors:  Cam Patterson; Andrea L Portbury; Jonathan C Schisler; Monte S Willis
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

4.  Contributions of increased efficiency and capacity of protein synthesis to rapid cardiac growth.

Authors:  H E Morgan; C J Beinlich
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

Review 5.  The role of ubiquitin ligases in cardiac disease.

Authors:  Monte S Willis; Ariana Bevilacqua; Thomas Pulinilkunnil; Petra Kienesberger; Manasi Tannu; Cam Patterson
Journal:  J Mol Cell Cardiol       Date:  2013-11-19       Impact factor: 5.000

6.  Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease.

Authors:  Monte S Willis; Jonathan C Schisler; Cam Patterson
Journal:  Future Cardiol       Date:  2008-01

7.  Muscle ring finger 1 mediates cardiac atrophy in vivo.

Authors:  Monte S Willis; Mauricio Rojas; Luge Li; Craig H Selzman; Ru-Hang Tang; William E Stansfield; Jessica E Rodriguez; David J Glass; Cam Patterson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-23       Impact factor: 4.733

8.  miR-322-5p targets IGF-1 and is suppressed in the heart of rats with pulmonary hypertension.

Authors:  Martin Connolly; Benjamin E Garfield; Alexi Crosby; Nick W Morrell; Stephen J Wort; Paul R Kemp
Journal:  FEBS Open Bio       Date:  2018-01-24       Impact factor: 2.693

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.